5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | NEUTRAL | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.39▼ | 1.39▼ | 1.39▼ | 1.32▲ | 1.28▲ |
MA10 | 1.40▼ | 1.39▼ | 1.40▼ | 1.32▲ | 1.14▲ |
MA20 | 1.40▼ | 1.41▼ | 1.36▲ | 1.28▲ | 0.95▲ |
MA50 | 1.41▼ | 1.34▲ | 1.33▲ | 1.12▲ | 0.84▲ |
MA100 | 1.40▼ | 1.33▲ | 1.31▲ | 0.90▲ | 0.99▲ |
MA200 | 1.35▲ | 1.28▲ | 1.18▲ | 0.80▲ | 1.30▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▼ | -0.008▼ | -0.002▼ | 0.000▲ | 0.050▲ |
RSI | 41.516▼ | 49.800▼ | 55.155▲ | 64.106▲ | 66.476▲ |
STOCH | 41.667 | 22.917 | 8.207▼ | 43.710 | 70.401 |
WILL %R | -87.500▼ | -91.667▼ | -95.455▼ | -35.484 | -13.750▲ |
CCI | -95.062 | -70.440 | -93.841 | 141.648▲ | 145.805▲ |
Monday, September 29, 2025 12:30 AM
Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.
|
Tuesday, September 16, 2025 09:29 AM
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August 2025[1] ...
|
Tuesday, September 16, 2025 04:16 AM
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced updates on enrollment progress, U.S. site ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
30/09/25 | 1.41 | 1.45 | 1.38 | 1.40 | 1,181,905 |
29/09/25 | 1.33 | 1.51 | 1.33 | 1.41 | 3,850,735 |
26/09/25 | 1.24 | 1.30 | 1.20 | 1.29 | 699,920 |
25/09/25 | 1.24 | 1.26 | 1.20 | 1.25 | 436,864 |
24/09/25 | 1.28 | 1.28 | 1.2301 | 1.25 | 530,288 |
23/09/25 | 1.33 | 1.3417 | 1.26 | 1.27 | 530,047 |
22/09/25 | 1.34 | 1.35 | 1.29 | 1.30 | 586,162 |
19/09/25 | 1.38 | 1.39 | 1.3208 | 1.36 | 656,879 |
18/09/25 | 1.37 | 1.40 | 1.32 | 1.36 | 1,274,851 |
17/09/25 | 1.30 | 1.38 | 1.27 | 1.35 | 1,571,964 |
|
|
||||
|
|
||||
|
|